Exclusive Summary

• Targeting a population of over 20 million new cancer patients annually, it is a first-line essential drug for CINV/PONV strongly recommended by NCCN and ESMO guidelines, ensuring robust global demand.
• With originator patents long expired, leveraging China's integrated pharmaceutical supply chain (API + FDF) ensures significant cost advantages and supply stability for global public tenders.
• The 3ml:3mg strength is the mainstream specification for adult single-dose administration, which, combined with ready CTD dossiers, enables overseas distributors to achieve rapid localized registration and capture high-margin market shares.